EGFR and non-small cell lung carcinoma: These micelles were approved in combination with cisplatin for the first-line treatment of patients with epidermal growth factor receptor (EGFR) mutation-negative and mesenchymal lymphoma kinase (ALK)-negative, nonsurgically resectable locally advanced or metastatic non-small cell lung cancer (NSCLC), presenting certain safety and efficacy advantages [92].